Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2025-02-14 Regulatory Filings
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Regulatory Filings Classification · 100% confidence The document is a regulatory disclosure regarding payment methods, payment periods, and dispute resolution mechanisms as required by the Subcontracting Act (Article 13-3). It is a specific, structured disclosure filing submitted to a regulatory body (DART/KRX) rather than a general report or announcement. Since it does not fit into categories like financial reports, earnings releases, or governance reports, it falls under the 'Regulatory Filings' category.
2025-02-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a mandatory disclosure for insiders (directors/executives) when their shareholdings change, specifically due to events like resignation or trading. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS), which covers insider transactions and changes in ownership status by company directors and executives.
2025-01-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This type of filing is a standard disclosure for insider shareholdings and transactions, which falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions and ownership status by company executives.
2025-01-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the change in share ownership by an executive (Lee Eon-hyung) of Celltrion Pharm, specifically noting a decrease in shares due to a gift (증여). This type of filing is a standard regulatory requirement for insider trading or changes in holdings by company directors/executives, which corresponds to the 'Director's Dealing' category.
2025-01-02 Korean
공정거래자율준수프로그램운영현황
Governance Information Classification · 100% confidence The document is a formal disclosure by Celltrion Pharm regarding its 'Compliance Program' (CP) for fair trade, including the appointment of a compliance manager and the establishment of internal governance systems. This type of regulatory disclosure regarding internal governance and compliance programs falls under the category of general regulatory announcements or governance-related filings. Since it does not fit into specific categories like financial reports, board changes, or shareholder meetings, it is best classified as a general regulatory filing.
2024-12-30 Korean
배당락 (주식배당)
Notice of Dividend Amount Classification · 100% confidence The document is a short notice regarding '배당락' (ex-dividend date) for Celltrion Pharm. It specifies the company name, stock type, reference price, and the date of the ex-dividend event due to a stock dividend. Since it is a brief announcement regarding a dividend event rather than a full report or a proxy solicitation, it falls under the category of dividend-related announcements.
2024-12-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.